×

Adult polycystic kidney disease and insurance. (English) Zbl 1480.91211

Summary: Adult polycystic kidney disease (APKD) is a single-gene autosomal dominant genetic disorder leading to end-stage renal disease (ESRD, meaning kidney failure). It is associated with mutations in either of two genes, APKD1 and APKD2, and although diagnosis is still mostly by ultrasonography rather than DNA-based tests, this may change in the future. Recent studies have shown that the rates of onset of ESRD associated with APKD1 mutations are much greater than those associated with APKD2 mutations, a form of genetic heterogeneity that differs from, for example, familial breast cancer. In this paper we model the the impact of mutations in APKD1 or APKD2 on critical illness insurance, extending our work [ibid. 7, No. 2, 93–115 (2003; Zbl 1084.62531)], which was based on studies predating DNA-based tests. We then extend the model to life insurance and show that the financial impact is strongly dependent on the availability of treatment (dialysis and transplant), but that if it is available, extra premiums for life insurance are modest. We show that genetic heterogeneity introduces a novel problem, because carrying an APKD2 mutation is less risky than having a family history of APKD. Thus, in jurisdictions where family history may be used in underwriting but genetic tests may not, it may be illegal to use knowledge that benefits the applicant.

MSC:

91G05 Actuarial mathematics
92C50 Medical applications (general)

Citations:

Zbl 1084.62531
PDFBibTeX XMLCite
Full Text: DOI

References:

[1] Abbot, K. and Agodoa, L. 2002a. Polycystic Kidney Disease at End-Stage Renal Disease in the United States: Patient Characteristics and Survival. Clinical Nephrology, 57(3): 208-214.
[2] Abbot, K. and Agodoa, L. 2002b. Polycystic Kidney Disease in Patients on the Renal Transplant Waiting List: Trends in Hematocrit and Survival. BioMed Central Nephrology, 3(7): 1471-1476.
[3] ABI. 1999. Genetic Testing: ABI Code of Practice (Revised August 1999), London: Association of British Insurers.
[4] ANZDATA. 2002. Annual Report Adelaide, Australia and New Zealand 2001. Data Registry
[5] Benjamin, B. and Pollard, J. H. 1980. The Analysis of Mortality and Other Actuarial Statistics, London: Heinemann.
[6] Churchill, D., Bear, J., Morgan, J., Payne, R., Mcmanamon, P. and Gault, H. 1984. Prognosis of Adult Onset Polycystic Kidney Disease Re-evaluated. Kidney International, 26: 190-193.
[7] Dalgaard, O. 1957. Bilateral Polycystic Disease of the Kidneys: A Follow-Up of Two Hundred and Eighty Four Patients and Their Families. Acta Medica Scandinavica, S328: 1-255.
[8] Daykin, C. D., Akers, D. A., Macdonald, A. S., Mcgleenan, T., Paul, D. and Turvey, P. J. 2003. Genetics and Insurance—Some Social Policy Issues (with Discussions). British Actuarial Journal, 9: 787-874. · doi:10.1017/S1357321700004360
[9] Dinani, A., Grimshaw, D., Robjohns, N., Somerville, S., Spry, A. and Staffurth, J. 2000. “A Critical Review. Report of the Critical Illness Healthcare Study Group”. London, U.K Paper presented to the Staple Inn Actuarial Society
[10] Fitzpatrick, P., Torres, V., Charboneau, W., Offord, K., Holley, K. and Zincke, H. 1990. Long-Term Outcome on Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases, 15(6): 535-543.
[11] Florijn, K., Chang, P., Van Der Woude, F., Van Bockel, H. and Van Saase, J. 1994. Long-Term Cardiovascular Morbidity and Mortality in Autosomal Dominant Polycystic Kidney Disease Patients after Renal Transplantation. Transplantation, 57(1): 73-81.
[12] Gabel, H. and Brynger, H. 1980. Renal Transplantation in Patients with Polycystic Kidney Disease in Gothenburg. Scandinavian Journal of Urololgy and Nephrology, 54: 76-78. Suppl
[13] Gabow, P., Johnson, M., Kaehny, W., Kimberling, W., Lezotte, D., Duley, I. and Jones, R. 1992. Factors Affecting the Progression of Renal Disease in Autosomal Dominant Polycystic Kidney Disease. Kidney International, 41: 1311-1319. · doi:10.1038/ki.1992.195
[14] Gui, E. H. and Macdonald, A. S. 2003. “Should Multiple Endocrine Neoplasia Be an Insurance Problem or Not?”. Heriot-Watt University. Research Report No. 03/2, Genetics and Insurance Research Centre
[15] Gutiérrez, M. C. and Macdonald, A. S. 2003. Adult Polycystic Kidney Disease and Critical Illness Insurance. North American Actuarial Journal, 7(2): 93-115. · Zbl 1084.62531
[16] GutiéRrez, M. C. and Macdonald, A. S. 2004. Huntington’s Disease, Critical Illness Insurance and Life Insurance. Scandinavian Actuarial Journal, : 279-313. · Zbl 1087.62115
[17] Hadimeri, H., Norden, G., Friman, S. and Nyberg, G. 1997. Autosomal Dominant Polycystic Kidney Disease in a Kidney Transplant Population. Nephrology, Dialysis and Transplantation, 12: 1431-1436.
[18] Harris, S. and Brown, E. 1998. Patients Surviving More than 10 Years on Haemodialysis: The Natural History of the Complications of Treatment. Nephrology Dialysis Transplantation, 13: 1226-1233.
[19] Hateboer, N., Bogdanova, N., Dijk, M., Coto, E., Saggar-Malik, A., San Millan, J., Torra, R., Ravine, D., Breuning, M. and For The European Pkd1-Pkd2 Study Group. 1999. Comparison of Phenotypes of Polycystic Kidney Disease Types 1 and 2. European PKD1-PKD2 Study Group. Lancet, 353: 103-107. · doi:10.1016/S0140-6736(98)03495-3
[20] Hoem, J. M. 1988. The Versatility of the Markov Chain as a Tool in the Mathematics of Life Insurance. Transactions of the 23rd International Congress of Actuaries, Helsinki, S, : 171-202.
[21] Johnson, A. and Gabow, P. 1997. Identification of Patients with Autosomal Dominant Polycystic Kidney Disease at Highest Risk of End-Stage Renal Disease. Journal of Medical Genetics, 34: 827-830.
[22] Macdonald, A. S. 2003a. Genetics and Insurance: What Have We Learned So Far?. Scandinavian Actuarial Journal, : 324-348. · Zbl 1092.91052
[23] Macdonald, A. S. 2003b. Moratoria on the Use of Genetic Tests and Family History for Mortgage-Related Life Insurance. British Actuarial Journal, 9: 217-237. · doi:10.1017/S1357321700004177
[24] Macdonald, A. S. 2004. “Genetics and Insurance”. In Encyclopaedia of Actuarial Science, Edited by: Teugels, J. L. and Sundt, B. 769-778. Chichester: John Wiley. 2
[25] McDonald, S. and Russ, G. 2002. Survival of Recipients of Cadaveric Kidney Transplants Compared with Those Receiving Dialysis Treatment in Australia and New Zealand, 1991-2001. Nephrology Dialysis Transplantation, 17: 2212-2219.
[26] Meier-Kriesche, H., Ojo, A., Port, F., Arndorfer, J., Cibrik, D. and Kaplan, B. 2001. Survival Improvement among Patients with End-Stage Renal Disease: Trends over Time for Transplant Recipients and Wait-Listed Patients. Journal of the American Society of Nephrology, 12: 1293-1296.
[27] Perrone, R., Ruthazer, R. and Terrin, N. 2001. Survival after End-Stage Renal Disease in Autosomal Dominant Polycystic Kidney Disease: Contribution of Extrarenal Complications to Mortality. American Journal of Kidney Disease, 38(4): 777-784.
[28] Rabbat, C., Thorpe, K., Russell, D. and Churchill, D. 2000. Comparison of Mortality Risk for Dialysis Patients and Cadaveric First Renal Transplant Recipients in Ontario, Canada. Journal of the American Society of Nephrology, 11: 917-922.
[29] Ravine, D., Walker, R., Gibson, R., Forrest, S., Richards, R., Friend, K., Sheffield, L., Kincaid-Smith, P. and Danks, D. 1992. Phenotype and Genotype Heterogeneity in Autosomal Dominant Polycystic Kidney Disease. Lancet, 340: 1330-1333. · doi:10.1016/0140-6736(92)92503-8
[30] Subramanian, K., Lemaire, J., Hershey, J. C., Pauly, M. V., Armstrong, K. and Asch, D. A. 2000. Estimating Adverse Selection Costs from Genetic Testing for Breast and Ovarian Cancer: The Case of Life Insurance. Journal of Risk and Insurance, 66: 531-50.
[31] Tsakiris, D., Jones, E., Brigs, D., Elinder, C., Mehls, O., Mendel, S., Piccoli, G., Rigden, S., Dos Santos, J., Simpson, K. and Vanrenterghem, Y. 1999. Deaths within 90 Days from Starting Renal Replacement Therapy in the ERA-EDTA Registry between 1990 and 1992. Nephrology Dialysis Transplantation, 14: 2343-2350.
[32] U.K. Transplant. 2002. U.K. Transplant Annual Report, 2001. U.K. Transplant—Bristol, U.K. Renal Registry
[33] United States Renal Diseases System. 1999. Annual Report of the United States Renal Diseases System, USRDS.
[34] Watson, M. and Torres, V. 1996. Polycystic Kidney Disease, Oxford: Oxford University Press.
[35] Wolfe, R., Ashby, V., Milford, E., Ojo, A., Ettenger, R., Agodoa, L., Held, P. and Port, F. 1999. Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation and Recipients of a First Cadaveric Transplant. New England Journal of Medicine, 341: 1725-1730. · doi:10.1056/NEJM199912023412303
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.